Serum LINC01127 serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes

BACKGROUND: This study aims to investigate the role of LINC01127 in sepsis and evaluate its potential clinical value. METHODS: This study included 102 sepsis patients and 102 controls matched for age and gender. Serum levels of LINC01127 and miR-34b-5p were measured using quantitative real-time PCR (RT-qPCR). Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic efficacy of LINC01127 for sepsis, while Kaplan-Meier curves evaluated its prognostic significance during 28-day follow-up. Lipopolysaccharide (LPS)-induced THP-1 cells were used to simulate an in vitro sepsis model. Enzyme-linked immunosorbent assay (ELISA) measured proinflammatory factor levels, and flow cytometry assessed apoptosis. RESULTS: Serum LINC01127 exhibited downregulation in sepsis-affected individuals, while miR-34b-5p was upregulated. ROC curve analysis demonstrated that LINC01127 possesses good diagnostic value for sepsis. Kaplan-Meier analysis showed that low LINC01127 levels were associated with poorer prognosis during the 28-day follow-up. Bioinformatics analysis successfully predicted a binding site for miR-34b-5p on LINC01127, and dual-luciferase reporter (DLR) and RNA immunoprecipitation (RIP) assays confirmed their target relationship. Cell experiments demonstrated that upregulating LINC01127 significantly reduced the apoptosis and inflammation triggered by LPS, while increasing miR-34b-5p expression markedly reversed these effects. CONCLUSION: LINC01127 may serve as a promising biomarker for sepsis, alleviating apoptosis and inflammatory responses through targeting miR-34b-5p. This offers novel insights into sepsis diagnosis and treatment.